Furthermore, we conducted survival analysis based on the methylation level of Septin9 categorized into high and low groups, and found no significant difference in survival rates between the mSeptin9 high-expression group and the low-expression group in CRC patients (Fig 3F and 3L, P > 0.05). The gene discussed is SEPTIN9; the disease is colorectal carcinoma.